Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Rituximab and NK Immunotherapy for B Lymphoma

NCT02843061 is registered in ClinicalTrials.gov with Fuda Cancer Hospital, Guangzhou as lead sponsor.

NCT NCT02843061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02843061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Rituximab and NK Immunotherapy for B Lymphoma
Lead sponsor
Fuda Cancer Hospital, Guangzhou
Phase
Phase 1/2
Overall status
Completed
Start date
July 1, 2016
Completion date
July 1, 2019
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma recurrent